secwatch.observer — SEC 8-K summary
======================================

Issuer:     enVVeno Medical Corp (NVNO)
CIK:        0001661053
Form:       8-K
Filed at:   2021-12-01T23:59:59+00:00
Accession:  0001493152-21-030154
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 5.07, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

enVVeno expects 9 SAVVE trial sites active; shareholders approve director elections, plan amendments
--------------------------------------------------------------------------------

- Elected Dr. Francis Duhay and Dr. Sanjay Shrivastava as Class I directors for terms ending at 2024 annual meeting.
- Ratified Marcum LLP as independent auditor for FY2021 with 6,085,415 for, 11,290 against, 9,074 abstain.
- Approved amendment to 2016 Omnibus Incentive Plan increasing authorized shares to 4,500,000 (2,458,617 for, 1,254,579 against).
- Approved evergreen provision requiring at least 20% fully diluted shares under plan (2,439,885 for, 1,273,777 against).
- By end of week, expects 9 sites active and enrolling in SAVVE U.S. pivotal trial for VenoValve.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661053/000149315221030154/0001493152-21-030154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661053/000149315221030154/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-030154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer